OBJECTIVE: The objective of the study is to evaluate costeffectiveness of two sequential treatments; with Fulvetsrant sequence and without Fulvestrant sequence in the treatment of postmenopausal women with hormone receptor-positive local advanced or recurrent metastatic breast cancer in Korea.
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NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES
Dranitsaris G 1 , Lidgren M 2 , Lundkvist J 2 , Coleman R 3 1 Augmentium Pharma Consulting, Toronto, ON, Canada, 2 I3 Innovus, Stockholm, Sweden, 3 Weston Park Hospital, Sheffield, UK OBJECTIVE: In patients with MBC, a common practice in Europe is to offer first line docetaxel or paclitaxel. However, one important drawback in their use is the potential for dose-limiting toxicity. An albumin-bound formulation (nab) of paclitaxel (Abraxane) was recently developed to overcome these safety drawbacks and to provide additional efficacy. To provide health economic data, a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel was conducted for the United Kingdom (UK), France, Germany, Italy and Spain. METHODS: The clinical data were obtained from a meta analysis of randomized trials. Health care resource use for the delivery of chemotherapy and the management of grade III/IV toxicity was collected from a survey of European medical oncologists and from the literature. Using the Time Trade-off technique, utilities were obtained from 70 female oncology nurses in the UK and France. RESULTS: Nab-paclitaxel had the most favourable safety profile with the lowest incidence of grade III/IV neutropenia, febrile neutropenia, anemia, emesis and stomatitis. This translated to lower overall costs for managing the grade III/IV toxicity relative to both docetaxel and paclitaxel (e.g. in France; €286 vs. €966 vs. €422). Using the median number of cycles administered and the cost of toxicity in each country, the overall cost for nab-paclitaxel was higher than conventional paclitaxel, but comparable to docetaxel. Overall, 47 of 70 (67.1%) respondents selected nab-paclitaxel as their preferred choice. As an alternative to paclitaxel, the incremental cost per QALY gained was lower for nab-paclitaxel than docetaxel in three of the five countries evaluated. CONCLUSION: Given its more favorable safety profile, improved efficacy and comparable overall cost, nab-paclitaxel can be considered a preferred option over docetaxel in MBC. As an alternative to paclitaxel, each of the European health care bodies must decide if the cost per QALY gained for that country represents good value.
PCN57
COST-UTILITY ANALYSIS OF ADJUVANT GOSERELIN AND ADJUVANT CHEMOTHERAPY IN PATIENTS WITH PREMENOPAUSAL BREAST CANCER
Cheng TF Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan OBJECTIVE: To compare the cost and utility of adjuvant Goserelin and adjuvant chemotherapy for premenopausal breast cancer patients in Taiwan. METHODS: A total of 564 premenopausal breast cancer patients were newly diagnosed since 1993. Their medical history and vital status were routinely reviewed and recorded. From July 2007 to December 2007, 105 patients with stage Ia-IIIa disease who received Goserelin for at least one year or received at least 6 cycles of chemotherapy as adjuvant therapy were interviewed to obtain the utility value by standard gambling (SG) and visual scale (VS) methods. The chemotherapy included four regimens: CMF (cyclophosphamide, methotrexate, 5-fluorouracil), TE (docetaxel, epirubicin), TEC (docetaxel, epirubicin, cyclophosphamide), and CEF (cyclophosphamide, epirubicin, 5-fluorouracil). The cost of this study was defined as the total medical cost (surgery, drugs, and all services provided costs) of standard practices from a payer perspective. The standard practices of Goserelin and chemotherapy were subcutaneous injection of 3.6 mg Goserelin every four weeks for two years and six cycles of CMF, TE, TEC, or CEF, respectively. Survival analysis was conducted by Kaplan-Meier method and weighted by utility measurements. RESULTS: Survival at 11 years derived from registry data for patients received Goserelin was better than patients received chemotherapy (100% vs. 75%). Combining the survival data with utility score from questionnaires, the utilityweighted life-years were higher in Goserelin group compared to chemotherapy group by SG and VS 8.81 vs. 6.83, 8.78 vs. 7 .14, respectively. The cost of Goserelin was lower than that of chemotherapy and ranged from NT$29,825 to 50,234 (US$918-1,545) when applying standard body surface of 1.5 m 2 and 1.8 m 2 about the calculation of chemotherapy doses. CONCLU-SION: Our data suggest the Goserelin had better survival, higher utility-weighted life-years, but less cost than chemotherapy in the adjuvant treatment of premenopausal patients with stage Ia-IIIa breast cancer in Taiwan.
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